Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $137.0 million.

  • Zevra Therapeutics' Total Liabilities rose 1245.68% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year increase of 1245.68%. This contributed to the annual value of $138.5 million for FY2024, which is 2534.6% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Total Liabilities stood at $137.0 million, which was up 1245.68% from $139.0 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Total Liabilities registered a high of $139.0 million during Q2 2025, and its lowest value of $5.4 million during Q3 2021.
  • In the last 5 years, Zevra Therapeutics' Total Liabilities had a median value of $47.3 million in 2023 and averaged $69.7 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Total Liabilities crashed by 9258.95% in 2021, and later surged by 67201.32% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Total Liabilities (Quarter) stood at $5.8 million in 2021, then surged by 590.71% to $40.2 million in 2022, then surged by 174.65% to $110.5 million in 2023, then rose by 25.35% to $138.5 million in 2024, then fell by 1.09% to $137.0 million in 2025.
  • Its last three reported values are $137.0 million in Q3 2025, $139.0 million for Q2 2025, and $131.7 million during Q1 2025.